By Fineline Cube 
China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) for its drug prusogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. The approval is for the drug’s use in improving blood sugar control among adult patients with type 2 diabetes (T2D).
Mechanism of Action
Prusogliptin functions by inhibiting DPP-4, which in turn increases the sensitivity of beta and alpha cells to glucose. This leads to a rise in endogenous active glucagon-like peptide-1 (GLP-1) levels. The increase in GLP-1 levels stimulates insulin secretion in response to glucose and enhances the inhibitory effect of glucose on glucagon secretion. As a result, prusogliptin effectively reduces blood sugar levels without causing hypoglycemia or weight gain.
Clinical Benefits
Clinical studies have demonstrated that prusogliptin has a lasting hypoglycemic effect, along with a low incidence of adverse reactions. This makes it a valuable addition to the treatment options available for patients with type 2 diabetes, offering a safe and effective alternative for blood sugar management.-Fineline Info & Tech